SCHEDULE 13G/A: BlackRock Discloses 14.0% Stake in Innoviva, Inc. Common Stock

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 14.0% of Innoviva, Inc.'s common stock as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 8,790,044 shares of Innoviva, Inc. common stock.
• This represents 14.0% of Innoviva, Inc.'s total outstanding common stock.
• BlackRock holds sole voting power over 8,659,479 shares and sole dispositive power over all 8,790,044 shares.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating previous ownership disclosures.
• The ownership data is current as of March 31, 2025, with the filing submitted on April 28, 2025.
• One of BlackRock's entities, iShares Core S&P Small-Cap ETF, is noted to hold more than 5% of Innoviva's common stock.
• BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Innoviva, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of ownership, providing no explicit positive or negative sentiment regarding the issuer's performance. The sentiment is neutral as it simply reports a significant, passive stake.

Positives

• BlackRock's significant 14.0% stake in Innoviva, Inc. may signal institutional confidence in the company's long-term prospects.
• The filing indicates a passive investment strategy, as BlackRock certifies the shares are not held for the purpose of changing or influencing control, which can provide stability to the company's current management and strategic direction.

Risks

• The document does not explicitly state risks related to Innoviva, Inc.'s operations or financial health. The primary risk mentioned is the standard disclaimer that the shares are not held for control purposes, which could be a risk if an activist investor were desired by other shareholders.

Future Outlook

The Schedule 13G filing does not provide any forward-looking statements or guidance regarding Innoviva, Inc.'s future performance or BlackRock's future investment intentions beyond the passive nature of the current holding.

Industry Context

Schedule 13G filings are standard disclosures by institutional investors who acquire more than 5% of a company's voting stock, indicating a passive investment intent. BlackRock, as one of the world's largest asset managers, frequently files such documents across numerous public companies, reflecting its broad portfolio management activities, often through index funds or passively managed strategies. This filing indicates BlackRock's continued significant, passive stake in Innoviva, Inc.

Stakeholder Impact

• Shareholders: BlackRock's significant stake (14.0%) could be viewed positively by other shareholders as it indicates a large, stable institutional investor holding a substantial position, potentially reducing volatility from smaller, more active traders.
• Management: The certification that BlackRock's holding is passive and not for control purposes suggests that management can continue its strategic direction without immediate pressure from this specific large shareholder, unless BlackRock decides to engage in Rule 14a-11 nominations.

Key Dates

Keywords

Innoviva Inc., BlackRock, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, SEC Filing, Equity Stake, Investment Management